Indications
Open Access TIMES Journals

Indications

Oncology · Hematology
Spine Surgery
Cardiovascular
Diabetes + Endocrinology
Pneumology
Ophthalmology
Gynecology · Urology
Dermatology · Immunology · Rheumatology
Neurology · Psychiatry
Gastroenterology
Infectiology · Anesthesiology · Pain
Primary Care

Open Access TIMES Journals

Oncology · Hematology
Spine Surgery
Cardiovascular
Diabetes + Endocrinology
Pneumology
Ophthalmology
Gynecology · Urology
Dermatology · Immunology · Rheumatology
Neurology · Psychiatry
Gastroenterology
Infectiology · Anesthesiology · Pain
Primary Care

Oncology · Hematology

Expert Opinions

healthbook TIMES

Oncology · Hematology >

Zanubrutinib showed a significant PFS benefit versus acalabrutinib in patients with R/R CLL in a MAIC analysis

Leukemia

Share:

EHA 2024

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

Multiple Myeloma (MM)

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

STARGLO: Glofitamab combination therapy shows significant benefits in patients with relapsed/refractory diffuse large B-cell lymphoma

Quizartinib significantly reduces relapse rates versus midostaurin in newly diagnosed patients with FLT3-ITD-positive AML, based on MAIC analysis

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Liso-cel demonstrates comparable efficacy and a more favorable safety profile versus axi-cel in the updated MAIC analysis of TRANSFORM and ZUMA-7

inMIND: Tafasitamab plus lenalidomide and rituximab improves PFS in patients with R/R FL

Contact us
About us
Privacy Policy & Disclaimer
Online Media 2025 Data
Imprint

healthbook is a registered trademark. Copyright © 2025 healthbook